期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 91, 期 3, 页码 245-247出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2018.02.011
关键词
Respiratory viruses; Point-of-care diagnostics; MERS
资金
- National Institute of Allergy and Infectious Diseases [HHSN272201400007C]
- Defense Advanced Research Projects Agency (DARPA)
Clinical samples were evaluated with the Mobile Analysis Platform (MAP) to determine platform performance for detecting respiratory viruses in samples previously characterized using clinical reverse transcriptase polymerase chain reaction assays. The percent agreement between MAP and clinical results was 97% for influenza A (73/75), 100% (21/21) for influenza B, 100% (6/6) for respiratory syncytial virus (RSV), and 80% (4/5) for negative specimens. The approximate limit of detection of the MAP was 30 copies/assay for RSV and 1500 copies/assay for Middle East respiratory syndrome coronavirus. (C) 2018 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据